Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients. (13th June 2012)

• Record Type: Journal Article
• Authors: Van der Speeten, K.; Govaerts, K.; Stuart, O. A.; Sugarbaker, P. H.
• Other Names: Li Yan Academic Editor.
• Is Part Of: Gastroenterology research and practice. Volume 2012(2012)
• Publication Date: 2012-06-13
• Subjects: Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33005
• DOI: 10.1155/2012/378064
• Languages: English
• ISSNs: 1687-6121

Abstract

Abstract : Background . The peritoneal surface is an acknowledged locoregional failure site of abdominal malignancies. Previous treatment attempts with medical therapy alone did not result in long-term survival. During the last two decades, new treatment protocols combining cytoreductive surgery with perioperative intraperitoneal and intravenous cancer chemotherapy have demonstrated very encouraging clinical results. This paper aims to clarify the pharmacologic base underlying these treatment regimens. Materials and Methods . A review of the current pharmacologic data regarding these perioperative chemotherapy protocols was undertaken. Conclusions . There is a clear pharmacokinetic and pharmacodynamic rationale for perioperative intraperitoneal and intravenous cancer chemotherapy in peritoneal surface malignancy patients.